#Sweden #Orexo #AmorphOX #Uppsala #Lisa Moore

Orexo's New Organizational Structure

Orexo AB, a prominent Swedish pharmaceutical company, has made significant modifications to its organizational structure and management team. This strategic decision follows the divestment of its product Zubsolv® in the United States and is aimed at reinforcing the development of new products, alongside progressing their innovative AmorphOX® technology.

The company recognizes the critical importance of maintaining expertise within the U.S. market to ensure new product development aligns with customer demand. Lisa Moore, previously part of Orexo's U.S. leadership team since May 2024, has taken on a new role as the Senior Vice President of Products and Portfolio Strategy. In her capacity, Moore will spearhead long-term product vision initiatives, ensuring that Orexo's portfolio effectively meets the needs of their customer base, while also guiding investment decisions that promote growth in the business.

With over 25 years of experience in the biopharma industry, Moore is a well-regarded leader in commercial strategy and product planning. Before joining Orexo, she served as Vice President, Global Commercial Strategy at Emergent, where she contributed significantly to the commercial evaluation of potential market opportunities. Moore's extensive experience includes leadership roles at prominent firms such as MedImmune, Parke-Davis, Baxter International, and Merck. She will be an integral member of Orexo's management team and will report directly to the CEO, Nikolaj Sorensen.

Notably, Robert DeLuca, who has led Orexo US Inc. since the establishment of its U.S. commercial organization in 2013, will be retiring from his position. DeLuca has played a vital role in building Orexo's business in the U.S., particularly through the successful marketing of Zubsolv and efforts to combat the opioid crisis. His leadership and commitment have been critical in shaping Orexo's presence in the U.S. market.

During this transitional period, Nikolaj Sorensen, Orexo's CEO and President, expressed gratitude towards DeLuca for his invaluable contributions over the past decade. As Orexo embarks on this new chapter, Sorensen emphasized the alignment of their organizational goals with the company's long-term objectives, including product development pipeline advancement and strategic partnership expansions.

DeLuca will remain in his role until May 2026, providing guidance on strategic initiatives and supporting the transition of Zubsolv® US operations to Dexcel Pharma USA. His advisory role will ensure a seamless changeover and continuity as Orexo charts its future path.

With its headquarters in Uppsala, Sweden, Orexo is committed to advancing treatments for severe health conditions. The organization is driven by its key innovation, AmorphOX®, which is a proprietary drug delivery technology designed to enhance the bioavailability and stability of medications. Orexo aims to meet present and future healthcare requirements while expanding its pipeline of clinical programs and maintaining a strong collaborative spirit with its research and development partners.

For more information about Orexo and its developments, visit www.orexo.com. Follow them on social media platforms such as X, LinkedIn, and YouTube for the latest updates.

Conclusion

In summary, Orexo's recent changes address the need for a nimble and focused approach to product development, as it positions itself to better meet unfulfilled customer needs in the evolving pharmaceutical landscape. The company's dedication to innovation underscores its commitment to improving patient healthcare outcomes.